Topic Hub
24 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 24 of 24 clinical reviews.
A clinical review of how empagliflozin (Jardiance) affects appetite, food cravings, and caloric intake, with primary-literature citations and practical prescribing guidance.
Read clinical reviewA clinical review of empagliflozin (Jardiance) use in patients with autoimmune conditions, covering immunological mechanisms, trial data, drug interactions, and monitoring protocols.
Read clinical reviewDoes Jardiance (empagliflozin) affect bone density or fracture risk? A physician-reviewed deep-dive into the clinical trial data, mechanisms, and monitoring guidance for patients and prescribers.
Read clinical reviewA clinician-level review of empagliflozin (Jardiance) and cancer risk signals, covering EMPA-REG OUTCOME, FAERS pharmacovigilance data, FDA labeling history, and current prescribing guidance.
Read clinical reviewA clinician-level review of empagliflozin's long-term cardiovascular effects, covering EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, mechanism of action, and practical prescribing guidance.
Read clinical reviewA physician-reviewed look at empagliflozin (Jardiance) and cognitive function, covering EMPA-REG OUTCOME, proposed brain-protection mechanisms, and what patients with type 2 diabetes or heart failure should know.
Read clinical reviewA clinical comparison of compounded empagliflozin versus branded Jardiance covering bioavailability, regulatory status, trial evidence, cost, and prescribing guidance for type 2 diabetes, heart failure, and CKD.
Read clinical reviewA GRADE-graded review of empagliflozin (Jardiance) evidence across type 2 diabetes, heart failure, and chronic kidney disease. Covers EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, EMPA-KIDNEY, and current ADA/ESC guideline recommendations with inline primary-source citations.
Read clinical reviewA physician-reviewed deep dive into empagliflozin (Jardiance) and its known effects on hair, skin, and related dermatologic conditions, including genital mycotic infections, urinary changes, and rare rash reports.
Read clinical reviewA clinician-level review of how empagliflozin (Jardiance) affects liver function, ALT, AST, hepatic fat, and MASLD, with primary-literature citations and dosing guidance.
Read clinical reviewA clinical review of empagliflozin (Jardiance) and its effects on mental health, mood, depression, anxiety, and cognitive function. Covers EMPA-REG OUTCOME, DKA risk, and practical guidance for patients and prescribers.
Read clinical reviewA physician-level review of how empagliflozin (Jardiance) alters substrate oxidation, resting energy expenditure, fat mass, and mitochondrial function. Includes EMPA-REG OUTCOME data, mechanistic detail, and dosing guidance.
Read clinical reviewA physician-reviewed deep dive into empagliflozin (Jardiance) dosing, the evidence base for sub-standard doses, cardiovascular and renal trial data, and what clinicians need to know before considering any off-label low-dose strategy.
Read clinical reviewEmpagliflozin (Jardiance) affects body composition through caloric deficit, osmotic diuresis, and metabolic shifts. Learn evidence-based strategies to preserve lean mass while taking this SGLT2 inhibitor.
Read clinical reviewWhy has your Jardiance (empagliflozin) stopped working? A clinician-level guide to diagnosing and correcting glucose plateaus, weight loss stalls, and blood pressure non-response, with primary-literature citations and a decision framework.
Read clinical reviewA physician-level guide to empagliflozin (Jardiance) use after bariatric surgery, covering pharmacokinetic changes, SGLT2-specific risks like euDKA, DKA prevention protocols, and cardiovascular benefit data from EMPA-REG OUTCOME and EMPEROR trials.
Read clinical reviewWhen should you stop Jardiance (empagliflozin) before surgery? This clinical guide covers the evidence-based hold window, SGLT2 inhibitor-associated euglycemic DKA risk, anesthesia considerations, and safe restart protocols.
Read clinical reviewStopping empagliflozin (Jardiance) can trigger glucose rebound, fluid retention, and loss of cardiorenal protection. Learn the clinical evidence, timelines, and how to stop safely.
Read clinical reviewA clinician-level review of empagliflozin's renal effects, covering EMPA-REG OUTCOME, EMPA-KIDNEY, mechanism of action, contraindications, and when the drug protects versus harms the kidney.
Read clinical reviewA physician-reviewed guide covering Jardiance (empagliflozin) seasonal use considerations, including summer dehydration risk, winter illness management, exercise and heat interactions, and practical dosing guidance for clinicians and patients.
Read clinical reviewA clinical review of empagliflozin (Jardiance) and sexual function, covering genital mycotic infections, testosterone, erectile dysfunction, libido, and urogenital side effects with primary-literature citations.
Read clinical reviewA clinician-level review of how empagliflozin (Jardiance) affects sleep architecture, nocturia, sleep-disordered breathing, and overnight glucose patterns, with primary-literature citations.
Read clinical reviewA week-by-week breakdown of what to expect in your first month on Jardiance (empagliflozin), including clinical timelines, side effects, and how to get the most from your prescription.
Read clinical reviewWhen and how to safely restart empagliflozin after illness, surgery, or hospitalization. Covers sick-day rules, DKA risk, renal thresholds, and a step-by-step restart protocol backed by primary literature.
Read clinical review